MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics

MoonRISe-2, a Phase 2 Dose Expansion Within the Study of Erdafitinib Intravesical Drug Releasing System (TAR-210) for Localized Bladder Cancer: Study Design and Baseline Characteristics

Sunday, May 17, 2026 9:40 AM to 9:48 AM · 8 min. (America/New_York)
Hall B, The Square, Learning Lab
Detail

Registered attendees

Christopher Pieczonka
Christopher Pieczonka
Director of Advanced TherapeuticsUS Urology Partners
Ricardo Rendon
Ricardo Rendon
Professor of UrologyDalhousie University And Queen Elizabeth II Health sciences centre

Log in

See all the content and easy-to-use features by logging in or registering!